Home / Resource Library / Brentuximab Vedotin Shows Promising Activity as First-Line Use in Classical Hodgkin LymphomaBrentuximab Vedotin Shows Promising Activity as First-Line Use in Classical Hodgkin Lymphoma NCCN 2022